Price | 1W % | 1M % | 3M % | 6M % | 1Y % | YTD % |
---|---|---|---|---|---|---|
-- | -- | -- | -- | -- | -- | -- |
AI Generated Qualitative Analysis
![AI](https://streamlined.nyc3.cdn.digitaloceanspaces.com/assets/ai-default.gif)
Your time is precious, so save it. Use AI to get the most important information from the business.
Learn about Amgen Inc.
Amgen Inc. News
Amgen Inc. Quantitative Score
![Website screenshot](https://streamlined.nyc3.cdn.digitaloceanspaces.com/website-screenshots/amgen-com.webp)
About Amgen Inc.
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell count in patients cancer; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; and Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization. It also markets Nplate, Vectibix, MVASI, Parsabiv, EPOGEN, KANJINTI, BLINCYTO, Aimovig, EVENITY, AMGEVITATM, Sensipar/Mimpara, NEUPOGEN, IMLYGIC, Corlanor, and AVSOLA. Amgen Inc. serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. It has collaboration agreements with Novartis Pharma AG; UCB; Bayer HealthCare LLC; BeiGene, Ltd.; Eli Lilly and Company; Datos Health; and Verastem, Inc. to evaluate VS-6766 in combination with lumakrastm (Sotorasib) in patients with KRAS G12C-mutant non-small cell lung cancer. It has an agreement with Kyowa Kirin Co., Ltd. to jointly develop and commercialize KHK4083, a Phase 3-ready anti-OX40 fully human monoclonal antibody for the treatment of atopic dermatitis and other autoimmune diseases; and research and development collaboration with Neumora Therapeutics, Inc. and Plexium, Inc. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.
Amgen Inc. Earnings & Revenue
Amgen Inc. Financials
Table Compare
Compare AMGN metrics with: | |||
---|---|---|---|
Earnings & Growth | AMGN | None | |
EPS (TTM) YoY Growth | -- | -- | |
Revenue (TTM) YoY Growth | -- | -- | |
Valuation (TTM) | AMGN | None | |
Price/Earnings Ratio | -- | -- | |
Price/Sales Ratio | -- | -- | |
Profitability & Efficiency (TTM) | AMGN | None | |
Net Profit Margin | -- | -- | |
Return on Equity | -- | -- | |
Financial Health (TTM) | AMGN | None | |
Debt/Assets Ratio | -- | -- | |
Assets/Liabilities Ratio | -- | -- | |
Amgen Inc. Income
Amgen Inc. Balance Sheet
Amgen Inc. Cash Flow
Amgen Inc. Financials Over Time
Analysts Rating
Strong Buy
Buy
Hold
Sell
Strong Sell
Metrics Scores
Metrics | Score |
---|---|
Discounted Cash Flows | Strong Buy |
Return on Equity | Strong Sell |
Return on Assets | Strong Sell |
Debt/Equity Ratio | Strong Sell |
Price/Earnings Ratio | Strong Sell |
Price/Book Ratio | Strong Sell |
Price Targets
Disclaimer: This 3rd party analysis information is for reference only and does not constitute investment advice.
Amgen Inc. Dividends
Yield (TTM) | Dividend (TTM) | |
---|---|---|
Infinity% | 8.7600 |
Payment Date | Dividend | Frequency |
---|---|---|
2024-06-07 | 2.25 | Quarterly |
2024-03-07 | 2.25 | Quarterly |
2023-12-08 | 2.13 | Quarterly |
2023-09-08 | 2.13 | Quarterly |
2023-06-08 | 2.13 | Quarterly |
Historical Market Cap
Shares Outstanding
Amgen Inc. Executives
Name | Role |
---|---|
Mr. Robert A. Bradway | Chairman, Chief Executive Officer & President |
Dr. David M. Reese M.D. | Executive Vice President & Chief Technology Officer |
Mr. Murdo Gordon | Executive Vice President of Global Commercial Operations |
Mr. Peter H. Griffith | Executive Vice President & Chief Financial Officer |
Mr. Esteban Santos | Executive Vice President of Operations |
Name | Role | Gender | Date of Birth | Pay |
---|---|---|---|---|
Mr. Robert A. Bradway | Chairman, Chief Executive Officer & President | Male | 1963 | 6.73M |
Dr. David M. Reese M.D. | Executive Vice President & Chief Technology Officer | 1963 | 3.4M | |
Mr. Murdo Gordon | Executive Vice President of Global Commercial Operations | Male | 1967 | 3.24M |
Mr. Peter H. Griffith | Executive Vice President & Chief Financial Officer | Male | 1959 | 3.07M |
Mr. Esteban Santos | Executive Vice President of Operations | Male | 1968 | 3.01M |
Amgen Inc. Insider Trades
Date | 31 May |
Name | MILES AMY E |
Role | Director |
Transaction | Acquired |
Type | A-Award |
Shares | 719 |
Date | 31 May |
Name | Kullman Ellen Jamison |
Role | Director |
Transaction | Acquired |
Type | A-Award |
Shares | 719 |
Date | 31 May |
Name | Klotman Mary E. |
Role | Director |
Transaction | Acquired |
Type | A-Award |
Shares | 719 |
Date | 31 May |
Name | Jacks Tyler |
Role | Director |
Transaction | Acquired |
Type | A-Award |
Shares | 719 |
Date | 31 May |
Name | ISHRAK OMAR |
Role | Director |
Transaction | Acquired |
Type | A-Award |
Shares | 719 |
Date | Name | Role | Transaction | Type | Shares |
---|---|---|---|---|---|
31 May | MILES AMY E | Director | Acquired | A-Award | 719 |
31 May | Kullman Ellen Jamison | Director | Acquired | A-Award | 719 |
31 May | Klotman Mary E. | Director | Acquired | A-Award | 719 |
31 May | Jacks Tyler | Director | Acquired | A-Award | 719 |
31 May | ISHRAK OMAR | Director | Acquired | A-Award | 719 |